Zhejiang Lihui Import Export Co., Ltd.

Zhejiang Lihui Import Co.,Ltd.

About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsPharmaceutical Capsule

Viagra Pharmaceutical Capsule Sildenafil Tablets Usp For Male Penile Erectile Dysfunction

Viagra Pharmaceutical Capsule Sildenafil Tablets Usp For Male Penile Erectile Dysfunction

Viagra Pharmaceutical Capsule Sildenafil Tablets Usp For Male Penile Erectile Dysfunction
Viagra Pharmaceutical Capsule Sildenafil Tablets Usp For Male Penile Erectile Dysfunction
Viagra Pharmaceutical Capsule Sildenafil Tablets Usp For Male Penile Erectile Dysfunction
Product Details:
Place of Origin: China
Brand Name: LiHui
Certification: Hplc ISO9001
Model Number: viagra
Payment & Shipping Terms:
Minimum Order Quantity: 100g
Price: Negotiated
Packaging Details: Foil Bag
Delivery Time: 3-7days after received payment
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: 5000Kg Per Month
Contact Now
Detailed Product Description
CAS: Viagra Color Or Appearance: White Crystalline Powder
Packing Specification: Aluminum Foil Bag Or Aluminum Tin 25 Kg/barrel Execution Standard: USP42
Product Purity: 99% The Product Level: Pharmaceutical Grade
Molecular Formula: Viagra Product Use: Erectile Dysfunction
High Light:

Viagra Pharmaceutical Capsule


Viagra Sildenafil Tablets Usp


Pharmaceutical Capsule Usp

The effective drug that treats male penile erectile dysfunction. Viagra. Sildenafil tablets
This product is a film-coated tablet, white to almost white after removing the coating. [1]
Sildenafil is suitable for the treatment of erectile dysfunction.
(1)25mg (2)50mg (3)0.1g
For most patients, the recommended dose is 50 mg, which is taken as needed about 1 hour before sexual activity; however, it can be taken at any time within 0.5-4 hours before sexual activity. Based on efficacy and tolerability, the dose can be increased to 100 mg (the maximum recommended dose) or reduced to 25 mg. Take it up to 1 time a day. In the absence of sexual stimulation, the recommended dose of sildenafil does not work.
The following factors are related to the increase in plasma sildenafil level (AUC): age 65 years or older (40% increase), liver damage (such as cirrhosis, 80% increase), severe renal damage (creatinine clearance rate [30 ml/min , An increase of 100%), and a powerful cytochrome P4503A4 inhibitor [ketoconazole, itraconazole (an increase of 200%), erythromycin (an increase of 182%), saquinavir (an increase of 210%)]. Since higher plasma levels may increase the efficacy and the incidence of adverse events at the same time, the starting dose for these patients is preferably 25 mg.
A study conducted in healthy subjects without HIV infection showed that Ritonavir can significantly increase the blood level of sildenafil (AUC increased by 11 times, see "Drug Interactions"). In view of this, it is recommended that patients taking ritonavir at the same time do not exceed the maximum dose of 25 mg every 48 hours.
Sildenafil can enhance the antihypertensive effect of nitrates, so patients who take nitric oxide donors and nitrates in any dosage form should not take sildenafil.
When sildenafil and alpha blockers need to be used together, before sildenafil treatment, the patient has been treated with alpha blockers to reach a stable state, and sildenafil should be taken from the lowest dose (see 【medicine interactions】).
Adverse reactions
Pre-IPO experience:
In clinical trials worldwide, more than 3,700 patients (aged 19-87) have taken sildenafil. More than 550 patients have been treated for more than one year.
In placebo-controlled clinical trials, the rate of discontinuation due to adverse events (2.5%) in the experimental group was not significantly different from that in the placebo group (2.3%). Adverse events are generally short-lived and mostly mild to moderate in nature.
In various forms of clinical trials, adverse events reported by patients in the experimental group are usually similar. In fixed-dose trials, the occurrence of certain adverse events increased with increasing dose. In general, flexible dose trials can better reflect the recommended dose usage of the drug, and the nature of adverse events seen in the trial is similar to that of the fixed dose trial.
In a flexible-dose, placebo-controlled clinical trial, sildenafil was taken as recommended (on-demand medication), and patients reported the following adverse events:
Although the incidence of the following adverse events was 2%, the incidence of the experimental group and the placebo group were the same. They are: respiratory infections, back pain, flu symptoms and joint pain.
In the fixed-dose trial, dyspepsia (17%) and visual abnormalities (11%) were more common in the 100-mg dose group than in the low-dose group. When the recommended dose range is exceeded, the performance of adverse events is similar to the previous one, but the frequency of reporting increases.
The following are adverse events with a rate of [2% in controlled clinical trials. It is not yet certain whether its occurrence is caused by sildenafil. Including incidents that may be related to medication, but omitting minor incidents and inaccurate reports.
Systemic reactions: facial edema, photosensitivity, shock, fatigue, pain, chills, accidental falls, abdominal pain, allergic reactions, chest pain, accidental injury.
Cardiovascular system: angina pectoris, atrioventricular block, migraine, syncope, tachycardia, palpitations, hypotension, orthostatic hypotension, myocardial ischemia, cerebral thrombosis, cardiac arrest, heart failure, abnormal electrocardiogram, myocardium disease.
Digestive system: vomiting, glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, dry mouth, abnormal liver function, rectal bleeding, gingivitis.
Blood and lymphatic system: anemia and leukopenia.
Metabolism and nutrition: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemia, hypernatremia.
Musculoskeletal system: arthritis, arthropathy, muscle pain, tendon rupture, tenosynovitis, bone pain, muscle weakness, synovitis.
Nervous system: Ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, dizziness, depression, insomnia, drowsiness, dreaminess, slow reflexes, and insensitivity.
Respiratory system: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, excessive sputum, cough.
Skin and its appendages: urticaria, herpes simplex, itching, sweating, skin ulcers, contact dermatitis, exfoliative dermatitis.
Special sensations: dilated pupils, conjunctivitis, photophobia, tinnitus, eye pain, deafness, ear pain, eye bleeding, cataracts, dry eyes.
Urogenital system: Cystitis, nocturia, frequent urination, enlarged breasts, urinary incontinence, abnormal ejaculation, genital edema, and lack of orgasm.
Experience after listing:
Cardiovascular System
After listing, the following serious cardiovascular adverse events related to the application of sildenafil have been reported: myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebral hemorrhage, transient cerebral ischemia, and hypertension. Most (though not all) of the above patients already have cardiovascular risk factors. Many of the reported incidents occurred during or just after sexual activity; some occurred when sexual activity was not performed shortly after taking sildenafil. There are also some reported incidents that occurred hours or even days after taking medication or sexual activity. For these events, it is still unclear whether they are directly related to sildenafil, or related to sexual activity, existing cardiovascular disease, a combination of the above factors, or other factors (for important cardiovascular information, see "Warning" ).
Special feeling:
There are individual reports of sudden hearing loss or loss after the market, which is time-related to the use of PDE5 inhibitors (including this product). Some of these patients may have underlying diseases or other factors that cause otology-related adverse events. Many cases have limited follow-up information. It cannot be determined whether sudden hearing loss or loss is directly related to the use of this product, whether it is related to the patient’s existing risk factors for hearing loss, nor can it be determined whether it is a combination of the above two factors or whether there are other reasons (see "【Note Matters]/Patient Information" section).
Other events
Other adverse events reported after the market that were time-related to the use of sildenafil but did not appear in the pre-marketing study include:
Nervous system: seizures and anxiety.
Urogenital system: prolonged erection time, priapism (see "Warning") and hematuria.
Special sensations: diplopia, transient vision loss or decreased vision, red eyes or eye congestion, eye burning, eye swelling and pressure, increased intraocular pressure, retinal vascular disease or bleeding, vitreous peeling, perimacular edema and nose Nv wait.
In the post-marketing application of PDE5 inhibitors, including Viagra, there are rare reports of non-arterial anterior ischemic optic neuropathy (NAION) related to the medication time. NAION is a disease that can cause vision loss including permanent loss. In most but not all cases, these patients have underlying anatomical or vascular underlying or risk factors for NAION, including but not limited to: low cupping Disc ratio, age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking.
It is not certain that these events are directly related to the use of PDE5 inhibitors; or are related to the patient's underlying vascular risk factors or anatomical defects; or a combination of the two; or are caused by other factors. (See "[Precautions]/Patient Instructions" section).
Hemolymphatic system: The clinical relevance of vascular occlusion crisis and ED men receiving Viagra is unclear.
Viagra Pharmaceutical Capsule Sildenafil Tablets Usp For Male Penile Erectile Dysfunction 0Viagra Pharmaceutical Capsule Sildenafil Tablets Usp For Male Penile Erectile Dysfunction 1
Due to the known effect of this product on the nitric oxide/cGMP pathway (see "Pharmacology and Toxicology"), sildenafil can enhance the antihypertensive effect of nitrates. Therefore, patients who take any dosage form of nitrate, whether taking it regularly or intermittently, are contraindications.
After taking sildenafil, when it is safe to take nitrates (if needed) is still unclear. According to the pharmacokinetic data of healthy volunteers, a single oral dose of 100 mg, the plasma sildenafil concentration after 24 hours is about 2ng/ml (peak plasma concentration is about 440 ng/ml) (see "Pharmacokinetics" ). Plasma sildenafil concentration in the following patients is 3-8 times higher than healthy volunteers 24 hours after taking the medicine: age 65 years or older, liver damage (such as cirrhosis), severe kidney damage (creatinine clearance rate below 30 ml/min), and Take strong inhibitors of cytochrome P4503A4 such as erythromycin. Although the blood concentration of sildenafil 24 hours after taking the drug is much lower than the peak concentration, it is not yet known whether nitrate ester drugs can be taken safely at this time.
Patients who are known to be allergic to any of the ingredients in this product are contraindicated.
General matters
While diagnosing erectile dysfunction, the underlying cause should be clarified, and an appropriate treatment plan should be determined after a comprehensive medical examination.
Before applying sildenafil to a patient, the following important issues must be noted:
PDE5 (phosphodiesterase type 5) inhibitors should be used with caution when combined with alpha-receptor blockers. PDE5 inhibitors (including this product) and α-receptor blockers are both vasodilators, and both have the effect of lowering blood pressure. When a vasodilator is used in combination, it can be expected that the effect on blood pressure may be cumulative. In some patients, the combination of these two types of drugs can significantly reduce blood pressure and cause symptoms of hypotension (such as dizziness, dizziness, and fainting) (see [Drug Interactions]).
Also note the following:
– Before receiving sildenafil treatment, the patient should have reached a stable state of alpha-blocker therapy. Patients with hemodynamically unstable patients taking alpha-blockers alone are at increased risk of developing hypotension symptoms after combined use of PDE5 inhibitors.
– For patients who have reached a stable state after receiving alpha-blocker therapy, PDE5 inhibitors should be taken from the lowest dose.
– For patients who have taken the ideal dose of PDE5 inhibitors, treatment with alpha blockers should start at the lowest dose. Taking PDE5 inhibitors at the same time, with the gradual increase in the dose of alpha blockers, may further reduce blood pressure.
– The safety of the combined use of PDE5 inhibitors and alpha blockers may be affected by other factors, including insufficient intravascular volume and other antihypertensive drugs.
Sildenafil dilates the blood vessels of the systemic circulation, which may enhance the antihypertensive effect of other antihypertensive drugs.
In the main clinical trials, patients taking multiple antihypertensive drugs at the same time are included. Another independent drug interaction study showed that when hypertensive patients taking 5mg or 10mg of amlodipine added 100mg of this product, the systolic and diastolic blood pressure were further reduced by an average of 8mmHg and 7mmHg (see [Drug Interactions]).
Patients with benign prostatic hyperplasia (BPH) took the alpha-blockers doxazosin (4mg) and sildenafil (25mg) at the same time, and the supine position systolic blood pressure and diastolic blood pressure were further reduced by an average of 7mmHg. If a larger dose of sildenafil and doxazosin (4mg) are taken at the same time, there are reports of symptoms of orthostatic hypotension in individual patients within 1 to 4 hours after taking the drug. Simultaneous administration of sildenafil in patients treated with alpha-blockers may cause symptoms of hypotension in some patients. Therefore, if the dose of sildenafil exceeds 25 mg, it should not be taken within 4 hours of taking alpha blockers.
It is currently unknown whether sildenafil is safe for patients with bleeding disorders and patients with active peptic ulcers.
Sildenafil should be used with caution in patients with the following diseases: anatomical malformations of the penis (such as penile deviation, cavernous fibrosis, Peyronie's disease), diseases that easily cause priapism (such as sickle cell anemia, multiple myeloma, leukemia) ).
The safety and effectiveness of other treatments for erectile dysfunction in combination with this product have not been studied. Therefore, joint use is not recommended.
Whether used alone or in combination with aspirin, this product has no effect on human bleeding time. In in vitro experiments, this product enhances the anti-human platelet aggregation effect of sodium nitroprusside (a nitric oxide donor). In rabbits under anesthesia, the combined use of heparin and sildenafil has an additive effect on the prolongation of bleeding time, but similar human studies have not been conducted.
Information for patients
The doctor should explain to the patient that sildenafil and nitrate are not taken at the same time (regardless of whether the latter is regular or intermittent use).
Doctors should inform patients that sildenafil has the potential to enhance the antihypertensive effect of alpha-blockers and other antihypertensive drugs. Taking sildenafil and alpha blockers at the same time may cause symptoms of hypotension in some patients. When sildenafil and alpha blockers need to be used in combination, before sildenafil treatment, the patient should have reached a stable state of alpha blocker therapy, and sildenafil should be taken from the lowest dose.
Doctors should explain to patients that sexual activity is potentially dangerous to the heart when cardiovascular risk factors exist. At the beginning of sexual activity, if symptoms such as angina, dizziness, nausea, etc. occur, the sexual activity must be stopped and these conditions should be discussed with the doctor.
Doctors should inform patients that if there is a sudden loss of vision in one or both eyes, they should immediately stop taking all phosphodiesterase type 5 (PDE5) inhibitors, including Viagra, and consult a doctor. This condition may be a manifestation of non-arterial anterior ischemic optic neuropathy (NAION). NAION is a disease that can cause vision loss including permanent loss. It is related to the time of medication in the post-marketing application of all PDE5 inhibitors. Rare report of NAION. It is not certain that these events are directly related to the use of PDE5 inhibitors or related to other factors.
Doctors should inform patients who have had single-eye NAION: Regardless of whether vasodilators such as PDE5 inhibitors have an adverse effect on them (see "[Adverse Reactions]/Post-Marketing Experience/Special Feelings" section), they are at risk of NAION again Will increase.
Doctors should inform patients that if hearing loss or loss occurs suddenly, they should stop taking PDE5 inhibitors (including this product) and seek medical attention as soon as possible. Such events can be accompanied by tinnitus and dizziness, and are reported to be time-related with PDE5 inhibitors (including this product). However, it cannot be determined whether such events are directly related to the use of PDE5 inhibitors or other factors (see [Adverse Reactions]/Pre-marketing experience section and Post-marketing experience section).
Doctors should warn patients: After foreign approval of this product, there have been a small number of reports of prolonged erection time (more than 4 hours) and priapism (painful erections more than 6 hours). If the erection continues for more than 4 hours, the patient should seek medical attention immediately. If the priapism is not treated immediately, the penile tissue may be damaged and may lead to permanent loss of erectile function.
The doctor should tell
Viagra Pharmaceutical Capsule Sildenafil Tablets Usp For Male Penile Erectile Dysfunction 2

Contact Details
Zhejiang Lihui Import Export Co., Ltd.

Contact Person: sales

Tel: +8613777515435

Send your inquiry directly to us (0 / 3000)

Other Products